13F Holdings
中文EN

PASG Passage BIO, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1787297 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY26.9%
TTM EPS YoY27.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-212.3%
ROA-69.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets99.8%
Debt / equity0.00x
Current ratio1.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.99x
Accruals ratio-0.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$1.50M$3.34M$4.09M$5.42M$4.31M$5.81M$7.74M$9.56M
SG&A expense$3.44M$6.87M$4.79M$4.92M$4.35M$4.52M$6.08M$4.71M
Operating income-$4.94M-$8.27M-$8.25M-$13.85M-$8.65M-$10.33M-$16.46M-$14.27M
Net income-$4.72M-$7.82M-$7.56M-$12.98M-$7.75M-$9.38M-$15.40M-$12.72M
EBITDA-$4.94M-$8.25M-$8.12M-$13.67M-$8.46M-$10.13M-$16.26M-$13.55M
EPS (basic)-1.47-2.44-2.36—-2.44-2.96-4.87—
EPS (diluted)-1.47-2.44-2.36—-2.44-2.96-4.87—
Weighted avg. shares (diluted)3.22M3.21M3.21M—3.18M3.17M3.16M—
Balance sheet
Cash & equivalents$20.16M$24.16M$33.34M$46.30M$52.77M$57.63M$63.36M$37.57M
Short-term investments$0$0$0$0$0$0—$39.18M
Current assets$20.79M$25.18M$34.74M$47.76M$55.73M$60.31M$66.67M$78.81M
PP&E, net——$826,000$4.11M$5.16M$5.34M$5.52M$9.33M
Total assets$20.79M$25.18M$36.46M$62.28M$74.16M$79.20M$86.01M$102.41M
Current liabilities$20.74M$20.72M$20.10M$23.08M$22.25M$19.80M$17.82M$19.36M
Total liabilities$20.74M$20.72M$24.71M$43.53M$43.04M$40.94M$39.30M$41.15M
Shareholders' equity$50,000$4.46M$11.75M$18.75M$31.12M$38.26M$46.71M$61.26M
Shares outstanding3.22M3.22M3.21M3.18M3.18M3.18M62.15M3.16M
Cash flow statement
Operating cash flow-$4.00M-$9.18M-$12.99M-$6.48M-$4.85M-$6.33M-$13.85M-$8.44M
Investing cash flow$3,000$0$20,000$0$0$585,000$39.63M$13.68M
Financing cash flow———$9,000$0——$47,000
Depreciation & amortization$0$25,000$129,000$177,000$200,000$200,000$201,000$719,000
Stock-based compensation$313,000$525,000$556,000$609,000$611,000$923,000$858,000$1.25M

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.